FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo, Lannett Deal (opens in new tab)

The Federal Trade Commission took action to protect American patients from higher drug costs by requiring Aurobindo Pharma Limited to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc.Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients, ranging from drugs used to prevent organ transplant reject...